RPG Life Sciences hunts larger API deals after recent ₹215 crore spree

RPG Life Sciences is actively searching for larger acquisitions in the active pharmaceutical ingredients (API) sector, building on recent deal-making activity that saw the company invest ₹215 crore, according to company officials.

With more than ₹500 crore of capital earmarked for expansion, the drugmaker is targeting businesses that can strengthen its position through differentiated chemistry capabilities, regulatory approvals, and enhanced export potential. The targeted assets would complement RPG Life Sciences' existing operations and broaden its competitive advantages in the global API market.

The acquisition strategy reflects RPG Life Sciences' ambitions to consolidate its standing in the pharmaceutical ingredients segment, a crucial component in drug manufacturing. By focusing on companies with established regulatory clearances and export infrastructure, the firm aims to accelerate growth while reducing entry barriers into new markets.

The API sector has attracted significant consolidation activity in recent years as manufacturers seek to diversify their product portfolios and geographic footprints. RPG Life Sciences' pursuit of larger deals underscores the ongoing consolidation trend within India's pharmaceutical ingredient industry, as domestic players increasingly eye strategic acquisitions to enhance scale and capabilities.